Agmatine is naturally created from the amino acid arginine and is known to modulate multiple neurotransmitter receptors, such as inhibiting NMDA, serotonin, nicotinic acetylcholine receptors. Agmatine also inhibits the synthesis of nitric oxide, a signaling molecule that can also function as a neurotransmitter. Promising research has shown that agmatine has the potential to protect the brain against injury. Agmatine is also known to lower tolerance to opioid painkillers, meaning it may have the capacity to be used in various neuropathic pain treatments and possibly even in treating drug addiction.
1. Piletz, John E et al. "Agmatine: clinical applications after 100 years in translation." Drug discovery today 18.17 (2013): 880-893.
2. Galea, Elena et al. "Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine." Biochemical Journal 316.1 (1996): 247-249.
3. Gilad, Gad M et al. "Agmatine treatment is neuroprotective in rodent brain injury models." Life sciences 58.2 (1995): PL41-PL46.
4. Kolesnikov, Yuri, Subash Jain, and Gavril W Pasternak. "Modulation of opioid analgesia by agmatine." European journal of pharmacology 296.1 (1996): 17-22.